Gene Biotherapeutics, Inc. — Operating Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/677b04f3-e4ed-49cf-8cec-dee78967fcc4/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2020 | $-1.3M | 2020-01-01 – 2020-12-31 | evidence 0001493152-22-008205 |
| FY 2019 | $-837.0k | 2019-01-01 – 2019-12-31 | evidence 0001493152-21-009535 |
| FY 2018 | $-513.2k | 2018-01-01 – 2018-12-31 | evidence 0001493152-21-009535 |
| FY 2017 | $-2.1M | 2017-01-01 – 2017-12-31 | evidence 0001493152-21-009535 |
| FY 2016 | $-2.8M | 2016-01-01 – 2016-12-31 | evidence 0001564590-17-014409 |
| FY 2015 | $-3.1M | 2015-01-01 – 2015-12-31 | evidence 0001564590-16-030523 |
| FY 2014 | $-3.6M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-198325 |
| FY 2013 | $-93.9M | 2003-12-22 – 2014-03-31 | evidence 0001193125-14-201188 |
| FY 2012 | $-8.3M | 2012-01-01 – 2012-12-31 | evidence 0001193125-14-144256 |
| FY 2011 | $-7.4M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-143157 |
| FY 2010 | $-6.8M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-143157 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Gene Biotherapeutics, Inc. — all facts · Revenue · Net Income